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“A few years ago, as the story goes, scientists at NASA developed an interest in the 
bumblebee. The lab folks reckoned that the little insect held some secrets of flight that 
may provide answers about operating in space. After all, they asked, how could such 
small wings produce efficient lift for a relatively large and hairy torso? And how could a 
round body and flight position that violated many principles of aerodynamics move so 
effectively through the air? Indeed, there was much to learn.  
 
So scientists set about studying the bumblebee to discover its flying secrets. As scientists 
always do, they hypothesized about, scrutinized, examined, dissected, measured, timed, 
filmed, observed, compared, quantified, and debated the bumblebee. After weeks of study 
they came to one conclusion: Bumblebees are not capable of flight. 
 
Fortunately, no one told the bumblebee. They go right on believing that flight is normal 
for them despite what the best minds in the scientific world know as fact.  
We can learn a lot from the bumblebee. The single most critical piece of the puzzle is 
believing in yourself and your capacity to succeed. The bumblebee thinks it can fly. 
Actually, the thought of anything else never even crossed its mind. It just keeps flying” 
- Adapted from Friel, J., The Triathlete’s Training Bible: Second Edition. 
 Velopress, p.10, 2004. 
 
This thesis is dedicated to the bumblebees out there, 
who never ask that people believe what they desire is possible, 
only to have faith that if the possibility exists, they can do it 
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Abstract 
The pyruvate dehydrogenase (PDH) complex regulates the oxidation of 
carbohydrates in mammals. Decreased activation of PDH following exhaustive exercise 
may aid the resynthesis of glycogen through increased activity of PDH kinase-4 (PDK4), 
one of four kinases that decrease the activity of the PDH complex. The purpose of this 
study was to examine the role of PDK4 in post-exercise glycogen resynthesis. Wild-type 
(WT) and PDK4-knockout (PDK4-KO mice) were exercised to exhaustion and were 
sampled at rest (Rest), at exercise exhaustion (Exh), and after two-hours post-exercise 
(Rec). Differences in feeding post-exercise led to the addition of a PDK4-KO group, pair-
fed (PF) with WT mice. Glycogen fully recovered in all Rec groups in muscle however 
remained low in the PF group in liver. Flux through PDH was elevated in PDK4-KO 
muscle with feeding and low in the PF group in both tissues. This suggests PDK4 may 
fine-tune flux through PDH during exercise recovery. 
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CHAPTER 1 - Introduction 
In mammalian tissues, the regulation of carbohydrate oxidation is controlled by 
the pyruvate dehydrogenase (PDH) complex. This enzyme complex is situated on the 
inner mitochondrial membrane and controls the formation of acetyl-CoA from 
carbohydrate derivatives through the following reaction: 
pyruvate + NAD
+
 + CoA --------> acetyl-CoA + NADH + H
+
 + CO2. 
Increasing the activity state of PDH leads to increases in the rate of carbohydrate 
oxidation (110), and therefore the PDH complex is inevitably responsible for the fate of 
glucose once entered the tissue. Compared to the body's fat stores, glucose stored in 
glycogen offers a quickly mobilized and oxidizable substrate for energy provision, 
however as these stores are not as abundant, adequate control of their oxidation through 
the PDH complex is necessary to maintain euglycemia. Uniquely, the PDH complex has 
been shown to be able to tailor the flux of oxidation acutely, to quickly adapt in response 
to metabolic perturbations such as the onset of exercise, as well as chronically, to allow 
for sustained long-term inhibition with situations such as fasting. As the PDH complex 
plays a vital role in whole body glucose homeostasis, the understanding of this complex 
may also be important during the regulation of glycogen resynthesis following exercise. 
The flux through PDH has been previously shown to decrease during exercise recovery 
(52, 70), favouring increased recycling of three-carbon intermediates such as lactate and 
alanine for glycogen resynthesis. Although an exact mechanism for this has yet to be 
determined, growing evidence suggests that PDH activation (PDHa activity) is attenuated 
during recovery by PDK4 (38, 78, 80), one of four regulatory PDH kinases. Therefore, 
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the purpose of this thesis was to further elucidate the role of PDH kinase isoform 4 in 
regulating the PDH complex post-exercise. 
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CHAPTER 2 - Literature Review 
Structure & Reactions of the PDH Complex 
The structure of the mammalian PDH complex is comprised of three enzymes that 
are responsible for transforming pyruvate into acetyl-CoA. The dihydrolipoamide 
acetyltransferase enzyme (termed E2) makes up the 60-subunit inner pentagonal-
dodecahedral core (reviewed in (111)). This E2 core establishes a framework from where 
a class of branching extremities extend that each contain a carboxyl-terminal catalytic 
domain, a binding domain for the pyruvate dehydrogenase enzyme (termed E1), and two 
further lipoyl domains (reviewed in (88)) (see Figure 1). Each of these divisions are 
connected through the use of linker hinge regions labeled H1, H2, and H3, in respect to 
their location when moving inward from the most distal region of the complex. Also 
extending from the E2 is a second class of branching limbs, linked through hinge regions, 
that work outward to connect a single lipoyl domain (L3) and the third enzyme, 
dihydrolipoamide dehydrogenase (E3), via an E3 binding protein (E3BP) (74, 116). The 
manner in which the E3-binding limb attaches to the complex is not well understood, 
however recent evidence suggests that the C-terminal inner domain of the E3 appendage 
may substitute that of the E1-bound limb at key locations around the enzyme (39). 
Considering this possibility, 12 of the 60 branching extremities of the complex would 
comprise the attachments for the 12 E3BPs and 24 E3 enzymes observed to be present in 
the complex (reviewed in (36)).  
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Figure 1 - The orientation and structure of A) the branching extremities off of the 
PDH E2, as laid out by Harris (36), and B) the inner E2 (left) and outer E1 and E3 
regions (right), as represented by Reed (89). 
 
The E1 enzyme is a 154 kDa, 2 2, TPP-dependent heterotetramer (6) that
 
binds 
to the complex via the E1 binding domain. The E1 catalyzes the initial two stages of the 
PDH reaction through decarboxylating pyruvate, releasing CO2, and reductively 
acetylating the L1 lipoyl moiety (reviewed by Roche (93)). The E1 possesses the only 
non-equilibrium reaction involved with the PDH complex (see Figure 2) that in turn fully 
commits pyruvate to oxidation. Furthermore, the distal portion of the E1 binding domain 
may act as a lever for which the remaining extremity can operate as a biological crane to 
interact with its surrounding environment, potentially assisting in substrate/product 
shuttling between catalytic sites and lipoyl moieties (reviewed by Reed (88)). Following 
the E1 reactions, the 3,600 kDa E2 enzyme (39) transfers the acetyl group produced by 
E1 to free coenzyme-A (CoA) to form acetyl-CoA (reviewed by Behal (7)). At this point 
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the reduced lipoyl moiety becomes reoxidized via two reactions catalyzed by the 110 kDa 
FAD-dependent E3 homodimer (reviewed by Mattevi (69)), reducing NAD
+
 to NADH.  
 
  
 
 
Figure 2 - The reactions of the PDH complex taken from Behal et al. (7). Take note 
that this diagram does not identify the near-equilibrium reactions of the 
dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide dehydrogenase (E3) 
enzymes. Abbreviations include: thiamine pyrophosphate (TPP); lipoyl moiety (Lip); 
pyruvate (CH3COCOO
-
); flavin adenine dinucleotide in its oxidized (FAD) and 
reduced (FADH) forms; nicotinamide adenine dinucleotide in its oxidized (NAD
+
) and 
reduced (NADH) forms; an acetyl group (CH3CO); and coenzyme-A (CoA or 
CoASH). 
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Regulation of the PDH Complex 
The PDH complex is regulated through a phosphorylation-dephosphorylation 
cycle by two unique classifications of isoenzymes (66). Four pyruvate dehydrogenase 
kinases (PDK1-4) and two pyruvate dehydrogenase phosphatases (PDP1-2) target the -
subunit of E1 (E1 ) where three regulatory serine phosphorylation sites are situated 
(117). Phosphorylation of any one of these sites by any PDK will sufficiently inactivate 
E1 on that branch of the complex and interestingly, has been shown not to hinder 
subsequent phosphorylation of other residues (56). The rate of phosphorylation, however, 
is site specific, with site 1 (serine-264) phosphorylation occurring most rapidly, followed 
by that of site 2 (serine-271), and then site 3 (serine-203) (55). Site 1 also seems to 
receive phosphorylation most frequently, well over that observed on sites 2 and 3 (96). In 
contrast, dephosphorylation of these three sites by a PDP occurs most rapidly at site 2, 
followed by site 3, and then site 1 (55). This reactivation of the complex has been shown 
to be attenuated by phosphorylation of multiple sites in tandem (104), which in addition 
to observations in vitro, has been demonstrated most dramatically in vivo in starved and 
diabetic rats (97). The extent of phosphorylation, however, occurs relative to the 
concentrations of intramitochondrial effectors stimulating the kinases (9). 
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The Pyruvate Dehydrogenase Kinases 
Each of the PDK isoforms (PDK1-4) are 45-47 kDa heterodimers comprised of a 
catalytic domain and a regulatory domain, where ATP and ADP bind to the catalytic 
domain, and pyruvate and the lipoyl group of L2 bind to the regulatory domain (101). 
Each of these isoforms interact through potassium-dependent association with the lipoyl 
domains of the complex (40) and demonstrates unique tissue expression and distinct 
kinetic properties in response to different cellular metabolites. 
 
PDK1 
PDK1 expression has been observed almost exclusively in the heart (9, 82), with 
only mild expression observed in soleus, red gastrocnemius (76), and other tissues (82). 
In humans, the PDK1 isoenzyme has been found to be 93% homologous with its rat 
counterpart, and in addition to its abundance in the heart, has exhibited expression to a 
lesser extent in skeletal muscle, liver, pancreas, brain, placenta, lung, and kidney (34). 
PDK1 is the only kinase to also phosphorylate site 3 of E1  (54, 56) and does so at a 
slightly slower rate than performed on site 1, but marginally faster than that of site 2 (54). 
Relative to the other kinases in vitro, PDK1 has exhibited a high specific activity and a 
strong insensitivity to the presence of ADP (9). Furthermore, PDK1 activity increases 
with a rise in the ratio of NADH/NAD
+
, which is further augmented with the addition of 
acetyl-CoA (see Table 1). 
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PDK2 
PDK2 is the most abundant PDK isoenzyme in mammals as it has been observed 
to be expressed ubiquitously in rodent (9) and human (34) tissues, with 93% homology 
between species. In vitro, PDK2 has a low specific activity (9) and incorporates much 
less phosphate into site 1 than the other isoenzymes, making dephosphorylation by the 
PDPs easier compared to when site 1 phosphorylation is performed by other kinases (54). 
In addition, this isoenzyme seems to display a preference towards site 1, and 
phosphorylates this site 19-fold faster than site 2 (54). Although PDK2 displays the 
greatest sensitivity towards binding of the non-metabolizable pyruvate analogue, 
dichloroacetate (DCA), the physiological relevance of the ability of DCA to inhibit any 
of the PDK isoenzymes occurs in the presence of ADP, where binding of DCA to the 
regulatory site lowers the inhibitory constant (Ki) of ADP so that both inhibitors may act 
synergistically to attenuate kinase activity (9, 84). It is worth noting that this effect may 
be increased with pyruvate, as pyruvate has been shown to be a more potent inhibitor of 
PDK2 than DCA (3). In contrast, PDK2 activity is stimulated in the presence of NADH 
only when accompanied by acetyl-CoA (see Table 1) (9). The unique sensitivity to both 
substrate-stimulation and product-inhibition by this isoenzyme makes PDK2 the 
predominant day-to-day regulator of PDH activity in most of the body's tissues. 
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PDK3 
In 1995, PDK3 was isolated for the first time in human tissues (34). Comparison 
of amino acid sequencing showed a 67-68% homology with PDK1 and PDK2. In humans 
PDK3 is found almost exclusively in the heart and skeletal muscle (34), however, unlike 
the other PDK isoforms, rodent PDK3 distribution is not analogous with that found in 
humans and is contrarily expressed predominantly in the testes, with smaller expression 
in lung, kidney, spleen, brain, and heart (9). In vivo experiments with this isoenzyme are 
difficult to perform as PDK3 expression is low and detection requires an antibody with 
high-specific binding (114). PDK3 phosphorylates site 1 approximately 6-fold more 
rapidly than site 2 (54), and in regards to its relative kinetic parameters, PDK3 has 
presented specific activity two-fold higher than any other isoform, higher sensitivity to 
inhibition by ADP, and relatively low sensitivity to the presence of DCA (see Table 1) 
(9). Experiments with this isoenzyme have additionally shown that it does not react to 
changes in the ratio of NAD
+
/NADH, and counterintuitively, PDK3 unexplainably 
displays decreased activity in the presence of acetyl-CoA (9).  
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 PDK1 PDK2 PDK3 PDK4 
Specific Activity 
 
 
650 ± 80 50 ± 5 1250 ± 200 400 ± 60 
Km for ATP ( M) 
 
 
60 ± 5 10 ± 1 50 ± 5 65 ± 6 
Ki for ADP ( M) 
 
 
370 ± 20 120 ± 20 80 ± 10 100 ± 15 
Ki for DCA (mM) 
 
 
1.0 ± 0.2 0.20 ± 0.05 8.0 ± 1.0 0.5 ± 0.2 
Ki for ADP in the 
presence of DCA 
( M) 
50 ± 10 35 ± 5 50 ± 10 200 ± 30 
Kinase activity 
NAD
+
/NADH 
(200:1) 
 
460 ± 10 33 ± 2 1020 ± 80 220 ± 15 
Kinase activity with 
NAD
+ 
/NADH (1:3) 
 
540 ± 15 44 ± 5 1150 ± 90 410 ± 20 
Kinase activity with 
NAD
+ 
/NADH (1:3) 
+ 50 m acetyl-CoA 
820 ± 30 105 ± 10 680 ± 50 340 ± 25 
 
Table 1 - Kinetic parameters of the different pyruvate dehydrogenase kinases 
(PDKs). Abbreviations include: Km (michaelis constant), Ki (inhibitory constant), 
DCA (dichloroacetate), and NAD
+
 and NADH (nicotinamide adenine dinucleotide; 
oxidized and reduced forms respectively). Information adapted from Bowker-Kinley 
et al. (9). 
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PDK4 
PDK4 was first cloned in 1996 during an investigation regarding genetic factors 
potentially related to type 2 diabetes in the native Pima Indians, a population with a high 
prevalence for the disease (95). In both rodents (9) and humans (95), PDK4 is abundantly 
expressed in heart and skeletal muscle, with lower quantities displayed in liver, lung, and 
kidney. PDK4 demonstrates a high specific activity (9) and shows no strong preference 
for site-specific activity, as site 1 phosphorylation by this isoenzyme occurs only 2.5-fold 
more rapidly than site 2 (54). Compared to PDK2, PDK4 is unique in that it has double 
the Ki towards DCA as well as a five-fold higher Ki towards ADP in the presence of 
DCA than any other kinase (see Table 1) (9). This property makes PDK4 distinctly 
unresponsive to local changes in pyruvate concentrations while allowing attenuation of 
PDH activity when necessary, regardless of the rate of pyruvate formation. The activity 
state of PDK4 occurs independent of acetyl-CoA concentrations and is stimulated solely 
through increases in the NADH/NAD
+
 ratio (9). PDK4 has also been shown to be 
responsive to increased lipid availability, such as with fasting (49) or a chronic high-fat 
diet (46, 48), reducing the flux of pyruvate to acetyl-CoA so it may potentially be used 
for gluconeogenesis.  
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The Pyruvate Dehydrogenase Phosphatases 
The 150 kDa PDP isoforms are made up of a 53 kDa catalytic subunit and a 96 
kDa regulatory subunit (58), which are together responsible for dephosphorylating the 
serine residues on E1 . Until the late 1990's it was believed that a single PDP isoform 
performed this in all tissues, however to date two isoenzymes have been identified to 
exist in both rodents (44) and humans (86).  
 
PDP1 
 The PDP1 isoform is expressed abundantly in the heart, brain, and testes, with 
minor expression in other tissues (44, 45). Additionally, PDP1 is the dominant 
phosphatase present in skeletal muscle (59, 61) and for this reason the sensitivity of 
PDP1 to local changes in Ca
2+
 concentrations is essential for proper activation of PDH 
(45). Previous research has identified Ca
2+
 as a dominant Mg
2+
-dependent activator of 
PDP activity (23, 58, 100, 105, 115) as well as an enhancer of PDP binding to L2 of the 
PDH complex (15, 106). Further demonstrating the responsiveness of this isoform to 
Ca
2+
, incubating PDP1 in elevated Ca
2+
 concentrations increases the maximum enzymatic 
velocity (Vmax) and simultaneously decreases the Km for Mg
2+
 (44), promoting enhanced 
activity.  
 
PDP2 
 Observed variation in the kinetic parameters of PDP between tissues led to the 
investigation, discovery, and cloning of the PDP2 isoenzyme in rodents (44). PDP2 has 
been observed to be expressed in 3T3-L1 adipocytes, liver, heart, brain, and kidney, with 
lesser expression in spleen, lung (44, 45), and skeletal muscle (59, 61). PDP2 has a 
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peptide sequence that shares 55% homology with its PDP1 counterpart and has 90% 
conservation in regions considered structurally vital to PDP function (44). In vitro, PDP2 
has demonstrated a relative insensitivity towards physiological concentrations of Ca
2+
, 
which may be an important trait of this isoenzyme in PDP2 expressing tissues. It has been 
shown in vitro, however, that in the presence of Ca
2+
 accompanied with high 
concentrations of Mg
2+
, PDP2 can elicit a higher maximal activity than PDP1 (44). Also 
interesting, spermine, which has been shown to stimulate mitochondrial Ca
2+
 uptake (63), 
elicits a 5-fold increase in the sensitivity of PDP2 to Mg
2+
 with a concomitant one-third 
decrease in its Vmax (44), suggesting that PDP2 activity may not be entirely independent 
of intracellular changes in Ca
2+ 
activity. 
Insulin has also been demonstrated to stimulate PDP2 activity (14, 57, 65, 71, 83), 
and although evidence suggests a direct role through the involvement of protein kinase C-
delta (14), a downstream target of insulin involved in multiple signaling pathways (64), 
mutagenesis studies disrupting the function of the tyrosine kinase insulin receptor have 
witnessed no impairments of the effect of insulin on PDP stimulation (32), leaving the 
exact mechanism of insulin action on PDP2 unknown. 
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Regulation of Carbohydrate Oxidation During Exercise 
During the early stages of prolonged exercise, muscle PDHa activity rises and 
begins to decline after a few hours of activity as exhaustion approaches, at which point 
muscle gradually relies more heavily on the oxidation of fat, sparing glycogen (18, 50, 
70, 108). This effect is also seen with endurance training and is further characterized by a 
lower activity of PDHa for a given workload (60). It is currently thought that these 
changes are mediated by alterations in the expression and stimulation of the regulatory 
isoenzymes of PDH. Although there is currently little evidence to suggest changes in 
PDP activity occur throughout an exercise bout, it has been demonstrated that PDK 
activity increases with observed decreases in PDHa activity (109). It is not entirely clear 
which of the PDK isoforms are responsible for attenuation of PDH during exercise, 
however PDK2 seems to be most probable, as it is the only kinase to increase expression 
following endurance training (62). Examining the specific role of PDK2 during exercise 
has proven difficult, however, due to the important role this kinase plays in the habitual 
regulation of the PDH complex. PDK2-knockout (KO) mice, which are devoid of PDK2 
expression, experience rapid compensation from the less abundant PDK1 during 
development (25), potently inhibiting the PDH complex during muscle contraction (24). 
Alternatively, PDK4 has also been implicated in PDH regulation during exercise, as 
studies have documented increased PDK4 transcription at exercise cessation (38, 70, 79) 
and further studies examining the role of PDK4 during muscle contraction in PDK4-KO 
mice have observed impaired PDH regulation and unrestricted PDHa activation at higher 
intensities of muscle contraction (Herbst et al., unpublished data), providing support for 
the involvement of PDK4 during exercise. 
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Glycogen Metabolism 
 At rest, liver glycogen stores supply the blood with adequate glucose to maintain 
plasma glucose concentrations, however in situations that tax these stores, such as with 
fasting or prolonged exercise (30), tissues such as the heart and skeletal muscle must rely 
on their own glycogen stores. Although the PDH complex ultimately determines whether 
the majority of carbohydrates will either be oxidized or used for gluconeogenic purposes, 
other metabolic factors exist upstream of glucose oxidation that regulate the formation 
and breakdown of glycogen. 
Glucose that enters the cell is converted to glucose-6-phosphate (G-6-P) by 
hexokinase (HK) and may then either enter glycolysis or be converted to glycogen 
(glycogenesis). G-6-P committed to glycogenesis becomes converted to glucose-1-
phosphate (G-1-P) by phosphoglucomutase, and then to UDP-glucose via UDP-glucose 
pyrophosphorylase, where it can be used as a substrate for glycogen synthesis (1) (see 
Figure 3). At the centre and beginning of each glycogen molecule lies a 37-38 kDa self-
glucosylating protein known as glycogenin. Glycogenin is located bound to the actin 
cytoskeleton (5) and uses UDP-glucose to perform the initial steps of glucosylation, 
adding 7-11 glucose molecules to itself in order to form an extending linear 
polysaccharide chain from which further glycogen growth can occur (2).  
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Figure 3 – The path of glycogenesis. Glucose is converted to glucose-6-phosphate 
(G-6-P) by hexokinase (HK) then to glucose-1-phosphate (G-1-P) by 
phosphoglucomutase (PGM). Finally, through the breakdown of uridine triphosphate 
(UTP), G-1-P is converted to UDP-glucose by UDP-glucose pyrophosphorylase 
(UDP-G PP) for use in glycogen synthesis. Glycolysis represents an early alternative, 
yet an almost inevitable fate of glucose. 
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Glycogen Synthase  
Glycogenin has limits to the extent it can self-glucosylate and cells must rely on 
additional enzymes to further promote glycogen synthesis. Glycogen synthase (GS) also 
uses UDP-glucose as a substrate and, with the assistance of a branching enzyme, adds 
diverging limbs to the polysaccharide chain bound to glycogenin to further expand the 
size of the glycogen molecule (see Figure 4). Two products are likely to form from this: a 
smaller 400 kDa intermediate product termed proglycogen, or an often final 10,000 kDa 
product called macroglycogen (67).  
 
 
 
Figure 4 – The Structure of a glycogen molecule. The filled circle in the centre 
represents the glycogenin protein from which a polysaccharide chain extends. 
Extending from this chain are further tiers of glucosyl branches synthesized by 
glycogen synthase. Figure adopted from Roche et al. (91). 
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In both humans and rodents, GS is expressed as separate isoforms in liver (73) 
and skeletal muscle (12), with ~70% sequence identity with one another, suggesting that 
the regulation of GS likely differs between tissues.  Furthermore, multiple kinases and 
phosphatases have also demonstrated the capability of phosphorylating and 
dephosphorylating GS to different degrees, in a tissue specific manner, to either enhance 
or reduce glycogen synthesis (10, 13, 28, 29, 72, 90-92), respectively. None of these 
regulatory enzymes are associated with GS exclusively, however, and each also plays 
additional roles in alternative metabolic signaling cascades, making their application in 
vivo more difficult to study. Therefore, although understanding the regulation of GS 
activity is continually advancing, the specifics regarding the relative importance of the 
various kinases and phosphatases in the covalent regulation of GS is still not entirely 
clear. 
GS activity is also subject to allosteric modification and is stimulated by the 
presence of G-6-P regardless of the state of phosphorylation, promoting enhanced 
glycogen synthesis with increases in glucose uptake (81). During recovery from exercise, 
attenuation of PDHa activity would theoretically play a role in further promoting 
glycogen synthesis, as reduced oxidation of carbohydrates would allow for greater 
recycling of carbohydrate derivatives towards glycogen synthesis.  
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Recovery from Exercise 
Glycogen concentrations in muscle (75), liver (4), and heart (19) are markedly 
decreased following exhaustive exercise, with rapid resynthesis of glycogen occurring 
post-exercise. Studies examining glycogen recovery following exhaustive exercise have 
shown that muscle glycogen resynthesis takes preference over liver replenishment, as rats 
fasted following exhaustive exercise demonstrate full recovery of muscle glycogen within 
24-hours despite the absence of dietary glucose intake (27). Furthermore, glycogen stores 
in skeletal muscle and heart have shown the ability to supercompensate following 
exercise, however where skeletal muscle glycogen has been shown to remain elevated for 
a few days following exercise (8, 31), heart glycogen recedes to baseline levels within 
24-hours following exhaustion (19, 98, 99). Glycogen repletion in either of these tissues 
is reliant on glucose provided to the circulation through diet, exogenously through the 
breakdown of remaining liver glycogen, as well as through gluconeogenesis from lactate, 
alanine, and glycerol (94).  
 Decreases in the activity of PDHa have been observed following exhaustive 
exercise in humans (52, 70), which hypothetically would allow for greater shift of 
pyruvate to lactate and alanine, leading to a greater recycling of these three-carbon 
substrates and improved glycogen resynthesis. Kimber et al. (52) examined the 
contributions of fat oxidation during recovery from glycogen depleting exercise and 
demonstrated an increased reliance on free fatty acids (FFA) along with decreased PDHa 
activity with glycogen recovery, supporting a role for PDHa attenuation post-exercise. 
PDK2 activity is potently stimulated by high acetyl-CoA concentrations, and although no 
mechanism was suggested for the observed inhibition of PDH in this study, the 
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concentrations of acetyl-CoA observed were low during recovery, suggesting that another 
kinase may be responsible for PDHa attenuation. Increased FFA availability has been 
shown to stimulate PDK4 expression (16), and although no changes in PDK4 protein 
content have been observed, increases in PDK4 transcription (38, 79, 80) and mRNA 
content (79, 80) have been observed following exercise in both human and rodent skeletal 
muscle, suggesting that PDK4 may be responsible for reducing PDHa activity following 
exercise-induced exhaustion. Depletion of glycogen stores post-exercise has also been 
suggested to share a link with increased PDK4 transcription (78) and protein expression 
(51), however studies that reduced glycogen content prior to exercise in humans also 
reduced the availability of carbohydrates and promoted increased reliance on FFA as a 
consequence. Increased FFA availability alone has been shown to stimulate peroxisome 
proliferator-activated receptor alpha (PPAR ) in the rodent model (17), which has been 
demonstrated to increase the transcription and protein expression of PDK4 (112). 
Therefore, although PDK4 may be the dominant mechanism for the inhibition of PDHa 
activity post-exercise, isolating the role of PDK4 during exercise recovery without 
stimulating PDK4 activity by other means has proven difficult. As such, the extent of 
PDK4 involvement during post-exercise glycogen resynthesis is still unclear. 
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Justification for the PDK4-KO Model 
In addition to the potential involvement of PDK4 during exercise and recovery, 
the expression of this isoenzyme has been shown to increase with changes in the 
abundance of carbohydrates, such as with diabetes (113, 114), long-term fasting (49, 76, 
103, 113, 114), and high-fat feeding (48, 77). The PDK4-KO model has been previously 
implemented to investigate the extent of PDK4 involvement under these circumstances 
(46, 48, 49) and would also provide an experimental approach to examine the role of 
PDK4 in exercise recovery without directly manipulating the availability of 
carbohydrates. PDK4-KO mice have been previously characterized and show increased 
resistance to the effects of high-fat feeding (46, 48), increased glucose tolerance, and an 
impaired ability to adapt to long-term fasting (49). In the resting fed state, PDK4-KO 
mice have higher PDHa activity in diaphragm and demonstrate compensation through 
increased expression of PDK2 in heart and kidney due to the absence of PDK4 (49). As 
no compensation by PDK2 has been shown to occur in liver or skeletal muscle of PDK4-
KO mice (36-38), examining the repletion of glycogen following exercise in PDK4-KO 
mice may provide insight into the potential role of PDK4 during glycogen resynthesis. 
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Statement of the Problem 
 To date, there is limited evidence to support that PDHa activity decreases during 
recovery following glycogen-depleting exercise. Furthermore, studies attempting to 
elucidate a mechanism by which PDHa activity is reduced have only measured changes 
in the transcriptional expression and mRNA content of PDK4, a regulatory kinase that 
experiences increased transcription with increases in FFA availability.  
 
Purpose 
 Therefore, the purpose of this study was to investigate a possible role for PDK4 in 
post-exercise glycogen recovery through examining the differences in the resynthesis of 
glycogen-depleted hindlimb and liver tissue of wild-type (WT) and PDK4-KO mice. 
 
Hypothesis 
 It was hypothesized that PDK4-KO mice would experience impairments in their 
ability to resynthesize muscle glycogen following exhaustive exercise with only minor 
impairments in the resynthesis of liver glycogen. 
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CHAPTER 3 – The following is a manuscript that will be submitted to the Journal of 
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Introduction 
 Muscle glycogen resynthesis after exercise has received much focus since 
Bergtröm and Hultman first identified enhanced glycogen synthesis following glycogen-
depleting exercise (8). Restoration of muscle glycogen is dependent on glucose supplied 
exogenously either through diet or gluconeogenesis. Although numerous precursors exist 
for hepatic gluconeogenesis, lactate and alanine represent the common products of 
muscle carbohydrate breakdown that are recycled through the liver for further glycogen 
synthesis (20, 22, 94). The mechanism for promoting the formation of these products 
post-exercise, however, is not fully understood. Decreased activity of the pyruvate 
dehydrogenase (PDH) complex may play a role, as the PDH complex is responsible for 
regulating the oxidation of carbohydrates in all mammalian tissues. PDH is inactivated 
and activated by four PDH kinases (PDK1-4) and two PDH phosphatases (PDP1-2), 
respectively, where PDK2 and PDP1 serve as the dominant regulators of PDH in resting 
skeletal muscle, and PDK2 and PDP2 are the principle regulators of liver PDH.  
A decrease in PDH activation (PDHa activity) in skeletal muscle during recovery 
would decrease carbohydrate oxidation, increase the reliance on fat oxidation, and 
potentially promote an increased shift of pyruvate to lactate and alanine in muscle. This 
would increase the availability of gluconeogenic substrates for the liver, promoting 
enhanced glucose output for glycogen synthesis in depleted tissues (26). Kimber et al. 
(52) examined the contribution of fatty acids over an 18-hour period following prolonged 
glycogen-depleting exercise in human skeletal muscle and observed decreased PDHa 
activity along with a higher reliance on fat oxidation during glycogen recovery. 
Furthermore, Mourtzakis et al. (70) also examined changes in muscle PDHa activity 
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following an exhaustive exercise bout in humans and observed decreased PDHa activity 
along with increases in PDK4 mRNA content in the following hours of recovery, 
suggesting PDK4 stimulation may be a mechanism that promotes decreased carbohydrate 
oxidation through reducing PDHa activity. Multiple studies have additionally 
demonstrated increased PDK4 transcription and mRNA production during exercise 
recovery (38, 70, 78, 79), supporting that changes in PDK4 activity may reduce flux 
through PDH post-exercise. This approach is problematic, however, as elevated fatty acid 
availability, such as seen following exercise (52, 70), would be expected to stimulate 
PDK4 expression through peroxisome proliferator-activated receptor alpha (PPAR ) 
(112), stimulating greater expression of PDK4 regardless of any need for PDK4 during 
recovery. Furthermore, PDK4 protein content has not been shown to change as a result of 
exercise, as no changes in PDK4 protein have been observed following 8-weeks of 
aerobic training in man (62). Therefore, although PDK4 may play a role in attenuating 
the activation of PDH to favour glycogen resynthesis, no evidence exists in the present 
literature to support this. 
As the activity of the individual PDK isoforms cannot be isolated, determining the 
metabolic contributions of each isoform to PDH regulation is difficult. Therefore, the 
present study took a loss of function approach to examine the role of PDK4 in the 
regulation of PDH during recovery from glycogen-depleting exercise in skeletal muscle 
and liver of wild-type (WT) and PDK4-knockout (PDK4-KO) mice. We hypothesized 
that PDK4-KO mice would be less able to reduce the activity of PDHa in skeletal muscle 
during recovery and that glycogen resynthesis would be impaired due to loss of 
carbohydrates to oxidation through the PDH complex. As PDK4 is expressed to a greater 
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extent in skeletal muscle (9), it was expected that this effect would be more pronounced 
during resynthesis in muscle than in the liver. 
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Methods 
Animals 
 Male PDK4-KO mice were generated from C57BL/6J mice by methods 
previously described (49) and were generously donated by Dr. Robert Harris (Indiana 
University School of Medicine). Male WT C57BL/6 mice were purchased from Charles 
River Laboratories (St. Constant, QC) to serve as paired controls. All mice were housed 
on a 12-hour:12-hour reverse light:dark cycle in a controlled environment in the Brock 
University Animal Care Facility for at least 1-week prior to being used and had ad 
libitum access to mouse chow (5015, LabDiet, Aberfoyle, On) and water before the 
experiment and during exercise recovery. This study was approved by the Brock 
University Animal Care Committee and conforms to the standards of the Canadian 
Council for Animal Care. 
 
Experimental Protocol 
Mice were provided a running wheel 1-week prior to the day of the experiment to 
allow for familiarization with running. Each genotype was paired and separated into three 
groups consisting of a resting condition, and two exercise conditions. Exercising mice 
were brought to a dark room and placed on a treadmill (EXER 3/6, Columbus 
Instruments International, Columbus, Ohio) for 5-minutes to allow for familiarization 
with the treadmill environment. The exercise protocol used was adapted from a protocol 
previously shown to deplete muscle glycogen stores (75). Mice began running on a 20
o
 
incline at an initial speed of 12-metres/minute with speed increases of 1m/min after 2-
minutes, 5-minutes, 10-minutes, and every additional 10-minutes of exercise until 
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exhaustion. Exhaustion was determined by an inability to remain halfway up the 
treadmill before falling off the moving belt four times consecutively despite being poked 
and blown on. Resting (Rest) mice (n=6) received no special intervention before surgery 
and exercising mice were killed either at exercise exhaustion (Exh) (n=8) or after 2-hours 
of recovery (Rec) (n=8), with post-exercise food and water intake recorded. As 
differences in post-exercise nutrition between WT and PDK4-KO mice were observed 
during the 2-hour recovery period, a group of pair-fed (PF) PDK4-KO mice (n=8) was 
included for analysis with food rations weighed out to match average WT food intake. 
Average time from exercise exhaustion to completion of the surgery in Exh was 
approximately 15-min. All mice were anesthetized by an intraperitoneal injection of 
diluted sodium pentobarbital (6mg/100mg of body weight) and blood glucose (Freestyle, 
Abbott, Illinois, USA) and lactate (Prolactate Test Meter, Arkray, Japan) concentrations 
were sampled from the heart using hand-held devices. Whole blood samples for glucose 
and lactate analysis were taken through intracardiac puncture under anesthesia prior to 
euthanasia. Hindlimb muscle and liver were immediately harvested and instantly freeze-
clamped for further analysis. 
 
Western Blotting 
Muscle tissue homogenization for WT and PDK4-KO mice at each time-point 
was performed on 10-15mg of tissue in a glass-on-glass potter homogenizer on ice in 
buffer containing 250mM sucrose, 100mM KCl, 5mM EDTA, with added protease 
(11836170001, Roach, QC) and phosphatase (04906845001, Roach, QC) inhibitors. 
Samples were diluted to a final concentration of 1.0 g/ L and loaded at 10 g 
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protein/lane. Proteins were separated by SDS-PAGE using a 10% separating gel for 
PDK2 and a 12% running gel for PDP1 before being transferred to polyvinylidene 
difluoride membrane. Membranes were incubated as previously described in 5% skim 
milk-TBST containing antibodies raised against PDK2 (25) (AP 7039b, Abgent), PDP1 
(61) (MC-049, Kamiya Biomedical Company), and actin (612656, BD Transduction 
Laboratories), and again in solution containing secondary antibodies raised against the 
primary antibody (24, 61). All proteins were detected and quantified as previously 
described (25) before being normalized to actin as a loading control. 
 
Glycogen and Metabolite Concentrations 
 Hindlimb muscle and liver were lyophilized, dissected free of connective tissue, 
and aliquoted for analysis of glycogen and metabolite concentrations. Glycogen aliquots 
were acidified in 2N HCl, heated at 100
o
C for 2-hours, rehydrated, and neutralized in 2N 
NaOH. Metabolite aliquots were extracted in 0.5M HClO4 and neutralized with 2.3M 
KHCO3. The concentrations of glycogen, glycogen precursors (glucose and G-6-P), and 
gluconeogenic precursors (lactate and alanine) were analyzed in triplicate using 
fluorometric techniques as previously described by Harris et al. (37) and modified by 
Green et al. (33).  
 
PDHa Activity 
Wet muscle and liver tissue were used for the determination of PDHa activity as 
previously described (21, 85). Tissue was homogenized in buffer (pH 7.8) containing 
200mM sucrose, 50mM KCl, 5mM MgCl2, 5mM EGTA, 50mM Tris HCl, 50mM NaF, 
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5mM DCA, and 0.1% Triton X-100. Samples were freeze-thawed and assayed for PDHa 
activity in assay buffer (pH 7.8) containing 14.4mM Tris base, 0.72mM EDTA, 1.44mM 
MgCl2, 1.1mM CoA, 1.1mM TPP, and 3.2mM NAD. The reaction was initiated with 
1.4mM pyruvate, sampled at 1-, 2-, and 3-minutes, and placed in 0.5M HClO4 to stop the 
reaction before being neutralized in 2.2M KHCO3 and analyzed for acetyl-CoA 
concentrations.  
 
Statistics 
A Student's t-test was used to analyze differences between genotypes in time to 
exhaustion, post-exercise nutritional intake, and protein content. A two-way analysis of 
variance (ANOVA) (genotype x condition (Rest, Exh, Rec)) was used to examine 
differences among conditions between WT and PDK4-KO mice in glycogen content, 
metabolite concentrations, and PDHa activity. Because PF mice were only sampled at 
Rec, a one-way ANOVA was used to examine differences between groups (WT, PDK4-
KO, PF) at Rec for glycogen content, metabolite concentrations, and PDHa activity. A 
Tukey's post-hoc test was performed if significance was detected (p<0.05). Due to low 
concentrations of muscle lactate and G-6-P in the PF group, some samples were not 
detectable and these groups did not meet the assumptions of normality and equal 
variances. Therefore a Kruskal-Wallis ANOVA on ranks with a Dunn post-hoc test was 
used to examine differences in muscle lactate and G-6-P concentrations at Rec between 
WT, PDK4-KO, and PF mice. All values are presented as mean ± S.E. 
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Results 
Exercise and caloric intake during recovery 
Absence of PDK4 had no effect on running time to exhaustion (p=0.898) (Figure 
5). In the two-hour period following recovery, a 2-fold difference in food consumption 
was observed in PDK4-KO mice (p=0.005) (Table 2). 
 
 
Figure 5 – Running time to exhaustion in wild-type (WT) and PDK4 knockout 
(PDK4-KO) mice (n = 16). Values are expressed as mean ± S.E. 
 
 
Table 2 - Post-exercise feeding and nutritional composition in wild-type (WT) and 
PDK4-knockout (PDK4-KO) mice (n = 8). Values are expressed as mean ± S.E. * 
Different from WT. 
 H2O 
(mL) 
Food (g) Tota l 
kcal 
Carb 
(kcal) 
Fat (kcal) Pro (kcal) 
WT 2.44  
± 0.36  
0.55  
± 0.09  
2.57  
± 0.41  
0.30  
± 0.05  
0.14  
 ± 0.02  
0.11  
± 0.02  
PDK4-KO 3.47  
± 0.68  
   1.01 * 
 ± 0.10  
   4.71 * 
± 0.48  
   0.55 * 
 ± 0.06  
   0.25 * 
± 0.03  
   0.20 * 
± 0.02  
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Glycogen concentrations 
As a result of exhaustive exercise, muscle glycogen was decreased to 42% of 
resting concentrations in WT mice and 51% in PDK4-KO mice, with no significant 
differences between genotypes. After a two-hour recovery period, muscle glycogen 
restored to resting levels in WT mice and PF mice, and supercompensated in PDK4-KO 
mice an additional 19% over resting levels (p<0.05) (Figure 6).  
Following exercise, liver glycogen concentrations decreased significantly to 16% 
of initial resting values in WT mice and 24% in PDK4-KO mice, again with no 
differences detected between genotypes. Following recovery, liver glycogen replenished 
to resting levels in WT and PDK4-KO mice, yet remained at only 49% of resting levels 
in PF mice (p<0.001) (Figure 6).  
 
Metabolite concentrations 
Blood glucose was lower in WT mice at exhaustion only, with no differences 
among groups following recovery (Figure 7). After recovery, blood lactate was lower in 
PF mice than Rec WT and PDK4-KO mice with no differences between genotypes at 
other time points. No differences were detected in muscle glucose or G-6-P 
concentrations between groups, however lactate and alanine were significantly lower in 
the PF group when compared to Rec WT and PDK4-KO mice (Table 3). In the liver, 
glucose concentrations decreased as a result of exercise in both genotypes, where after 
recovery, glucose returned to resting values in PDK4-KO mice, recovered partially in 
WT mice, and remained at low in PF mice (p<0.001) (Table 4). 
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Figure 6 – Glycogen concentrations in (A) muscle and (B) liver at rest, exhaustion 
(Exh), and recovery (Rec) from exercise (n = 5-8). WT, wild-type; PDK4-KO, PDK4-
knockout; PF, pair fed PDK4-KO.  Values are presented as mean ± S.E. † Different 
than rest within a genotype. * Different than WT for a given time-point. § Different 
than Rec PDK4-KO. 
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Figure 7 – Blood A) glucose and B) lactate concentrations at rest, exhaustion (Exh) 
and recovery (Rec) (n = 6-8). WT, wild-type; PDK4-KO, PDK4-knockout; PF, pair 
fed PDK4-KO. Values are expressed as mean ± S.E. † Different than rest within a 
genotype. * Different than WT for a given time-point. § Different than Rec PDK4-
KO. 
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Table 3 – Muscle metabolite concentrations at rest, exhaustion (Exh), and recovery 
(Rec) (n = 5-8). WT, wild-type; PDK4-KO, PDK4-knockout; PF, pair fed PDK4-KO. 
Values are expressed as mol/g dry weight ± S.E. † Different than rest within a 
genotype. * Different than WT for a given time-point. § Different than Rec PDK4-
KO. 
 
 
 
Table 4 – Liver metabolite concentrations at rest, exhaustion (Exh), and recovery 
(Rec) (n = 5-8). WT, wild-type; PDK4-KO, PDK4-knockout; PF, pair fed PDK4-KO. 
Values are expressed as mol/g dry weight ± S.E. † Different than rest within a 
genotype. * Different than WT for a given time-point. § Different than Rec PDK4-
KO. 
 
 Rest Exh Rec 
 WT KO WT KO WT KO PF 
Muscle        
Glucose 4.3  
± 1.5 
4.7  
± 0.6 
2.5 
± 0.8 
3.2  
± 0.8 
4.6 
± 0.5 
3.4 
± 0.5 
3.8 
± 0.2 
G-6-P 8.1 
± 3.0 
8.2 
± 2.7 
1.5  
± 0.7  
4.5 
± 1.1 
8.5 
± 2.7 
7.9 
± 1.7 
2.9 
± 0.4 
Lactate 23.0 
± 8.6 
9.8  
± 4.5 
8.0  
± 2.2 
8.5  
± 1.1 
16.8 
± 5.3 
14.7  
± 3.7 
3.7 *§ 
± 1.5 
Alanine 5.4  
± 2.0 
4.5  
± 1.6 
6.0  
± 1.5 
5.0  
± 2.0 
4.8  
± 1.1 
7.0  
± 1.3 
3.0 *§ 
± 0.8  
 
 Rest Exh Rec 
 WT KO WT KO WT KO PF 
Liver        
Glucose 86.5  
± 8.8 
65.3  
± 9.6 
17.3  
± 0.1  
34.4  
± 9.2  
56.0  
 ± 7.8 
66.6 
± 7.8 
27.1 *§ 
± 5.1 
G-6-P 1.8  
± 0.4 
2.2  
± 0.4 
0.7  
± 0.1 
1.01  
± 0.2 
1.4  
± 0.4 
2.7  
± 1.1 
1.4  
± 0.3 
Lactate 31.0  
± 5.0 
29.9  
± 7.8 
6.7  
± 3.4 
8.2  
± 2.8 
22.1  
± 3.7 
29.2  
± 3.1 
19.8 
± 7.9 
Alanine 8.8  
± 3.3 
6.5  
± 2.4 
3.6  
± 0.7 
11.0  
± 1.5 
14.9  
± 3.3 
15.8  
± 8.6 
12.4  
± 3.7 
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Activity of PDHa  
Muscle PDHa activity was greater in PDK4-KO mice at Rec than Exh (p<0.05), 
where no differences were detected in WT mice between time points (Figure 8). Liver 
PDHa activity increased from Exh to Rec in both WT and PDK4-KO mice.  PF mice had 
lower PDHa activity than WT and PDK4-KO mice in both muscle (p<0.05) and liver 
(p<0.05). 
 
Protein content of PDH regulatory enzymes 
 The absence of PDK4 in this study was confirmed in PDK4-KO mice through 
genotyping liver and muscle tissue through polymerase chain reaction (PCR; Pengfei Wu 
and Robert Harris, data not shown) as previously described (49). PDK2 and PDP1 protein 
concentrations were not significantly different between genotypes (Figure 9). 
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Figure 8 – PDHa activity in A) muscle and B) liver at exhaustion (Exh) and recovery 
(Rec) (n = 6-8). WT, wild-type; PDK4-KO, PDK4-knockout; PF, pair fed PDK4-KO. 
Values are expressed as mol/min/g wet weight ± S.E. ‡ Different than Exh within a 
genotype. * Different than WT for a given timepoint. § Different than Rec PDK4-KO. 
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Figure 9 – Muscle protein content of PDK2 (n = 12) and PDP1 (n = 20) of wild-type 
(WT) PDK4-knockout (PDK4-KO) mice (n=16). Typical blots are shown in inset. 
Values are expressed as mean protein concentration normalized to actin ± S.E. 
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Discussion 
The present study investigated the involvement of PDK4 in reducing PDHa 
activity post-exercise and found that 1) PDK4 plays a role during recovery from 
exhaustive exercise, however, 2) contrary to our hypothesis, the absence of PDK4 does 
not compromise glycogen resynthesis in skeletal muscle, but 3) causes increased feeding 
in PDK4-KO mice during recovery, and 4) leads to impaired hepatic glycogen 
resynthesis in PDK4-KO mice when pair-fed (PF) with WT mice. 
In this study, the exercise protocol used was successful in depleting glycogen 
concentrations in both skeletal muscle and liver. In skeletal muscle, full recovery of 
glycogen was observed during the two-hour recovery period in WT and PDK4-KO mice 
and interestingly, the 2-fold greater caloric intake observed in PDK4-KO mice during 
recovery had provided initial evidence that PDK4 may be involved during exercise 
recovery. The resulting 1.2-fold supercompensation of muscle glycogen in PDK4-KO 
mice, however, was unexpected, as we had alternatively hypothesized during 
experimentation that the greater caloric intake observed during recovery was indicative of 
greater carbohydrate oxidation through uninhibited PDHa activity, and that PDK4-KO 
mice would therefore show impaired muscle glycogen resynthesis. Furthermore, when 
PDK4-KO mice were pair fed (PF) with WT mice, skeletal muscle glycogen fully 
recovered despite the restriction of calories, which was contrary to our original 
hypothesis. As PDHa activity was not different between WT and PDK4-KO mice at 
exhaustion or recovery, and was found to be lower in the PF group, these results would 
suggest that the absence of PDK4 does not have a direct effect on the resynthesis of 
skeletal muscle glycogen following exercise. 
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Although liver glycogen resynthesized to the same degree in recovered WT and 
PDK4-KO mice, mice in the PF group demonstrated decreased liver glycogen 
resynthesis. As muscle glycogen recovered fully in these mice, this would suggest that 
muscle glycogen resynthesis takes priority over glycogen resynthesis in the liver. This is 
in support of existing evidence demonstrating preference for glycogen resynthesis in 
skeletal muscle following exercise. For example, rats fasted for 24-hours following 
exhaustive exercise demonstrated complete recovery of glycogen stores in skeletal 
muscle, with no recovery observed in the liver during the 24-hour fast (27). Similarly, 
Maehlum et al. (68) also demonstrated increased preference of muscle over liver for the 
incorporation of glucose into glycogen following glycogen-depleting exercise in humans. 
Therefore, compromised liver glycogen resynthesis in PF mice in this study emphasizes 
the priority placed on muscle glycogen synthesis and offers indirect evidence that glucose 
regulation is impaired in skeletal muscle of PDK4-KO mice, particularly with limited 
caloric availability. Where WT mice appear to demonstrate a balance between 
carbohydrate oxidation and lactate and alanine formation in skeletal muscle, PF mice 
display a reduced ability to form these gluconeogenic precursors, which may indicate a 
reduced ability to regulate carbohydrate oxidation. Although no significant differences 
were observed in PDHa activity in skeletal muscle between WT and PDK4-KO mice, 
more subtle physiological impairments may exist in PDK4-KO mice, which is supported 
by the reduced formation of lactate and alanine in skeletal muscle of the PF group. This 
theory would also explain the two-fold increase in caloric intake in PDK4-KO mice fed 
ad libitum during recovery, as greater carbohydrate availability may have been required 
to produce the same concentration of gluconeogenic precursors (Figure 10).  
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Figure 10 – Summary of findings and suspected pathways in WT, PDK4-KO, and PF 
mice during recovery from exercise. WT mice (top) represent the expected fates of 
carbohydrates during recovery, where increased feeding in PDK4-KO mice (middle) 
when fed ad libitum is hypothesized to compensate for potential loss through PDH. 
PF mice (bottom) have reduced carbohydrate availability for compensation and 
therefore appear to have reduced gluconeogenic recycling as evidenced by decreased 
muscle concentrations of glucose and alanine. Abbreviations include glucose (Glu), 
glucose-6-phosphate (G-6-P), pyruvate (Pyr), lactate (Lac), alanine (Ala), & glycogen 
(Gly). 
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  It has been previously shown that the PDP isoforms are able to partially override 
PDK-induced inhibition of PDHa activity during exercise. Kiilerich et al. (51) examined 
the degree of PDHa activation in exercised men fed a high-fat diet and observed that 
although PDK4 protein expression increased as a result of high-fat feeding, PDHa 
activity still increased with exercise, but not to the same extent as controls, indicating a 
reduced ability of PDP to activate the PDH complex. Furthermore, Herbst et al. 
(unpublished data) observed that with fasting, previously shown to increase PDK4 
protein expression (113), PDHa activity was not different in incubated EDL muscle of 
fed and fasted WT mice during stimulation, but was 2-fold greater in PDK4-KO mice. 
Where the PDPs were able to only partially override the fasting-induced stimulation of 
PDK4, the absence of PDK4 led to uninhibited PDHa activity. Taken together, the results 
of these studies suggest that the role of PDK4 during exercise and muscle contraction 
may be to work antagonistically to the PDPs to regulate small changes in PDHa activity, 
preventing full activation of PDH. Where PDP stimulation may work to rapidly 
dephosphorylate PDH, increasing the rate of carbohydrate oxidation, PDK4 may work to 
phosphorylate and fine-tune the extent to which PDH dephosphorylation may occur, 
balancing PDHa activity. Relative to the abundantly expressed PDK2 isoform, PDK4 is 
relatively insensitive to inhibition by pyruvate and has an 8-fold greater specific activity 
(9), making PDK4 ideal for maintaining a degree of PDH phosphorylation during PDP-
stimulated dephosphorylation in the presence of insulin. This effect of fine-tuning PDHa 
activity was also observed in the present study, as PDHa was greater within PDK4-KO 
mice at recovery than exhaustion, where this was not true in WT mice, suggesting that 
the activation of PDH is greater in PDK4-KO mice with feeding. Insulin is a known 
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stimulator of PDP2 (44) and it is likely that increases in insulin with feeding triggered 
PDP2 stimulation and therefore increased PDHa activity during recovery. Although it is 
possible that the differences in PDK4-KO mice may have been due to an insulin response 
from a 2-fold greater consumption of calories in PDK4-KO mice during recovery, it is 
also possible that the greater PDHa activation in PDK4-KO mice at recovery is a result of 
the absence of PDK4 in reducing PDH activation in the presence of PDP stimulation. 
Hypothetically, increased PDK4 activity during this time would decrease PDHa activity 
enough to balance carbohydrate oxidation with the production of lactate and alanine, 
allowing for gluconeogenic recycling and further glycogen resynthesis in both muscle 
and liver. This theory is supported by previous research that demonstrated reduced 
glycogen resynthesis and lactate formation during post-exercise recovery with the 
inhibition of PDK activity by DCA infusion (26). With sufficient availability of food in 
the present study, PDK4-KO mice would have had similar metabolic properties to PDK4-
KO mice in the PF group early in recovery. With limited caloric availability however, 
food was consumed faster in the PF group than in WT mice, and PF mice would have 
completed any metabolic processes resulting from feeding by the end of the two-hour 
recovery period. As muscle glycogen was fully recovered by this time, this would suggest 
that PDK4 may have greater importance early in recovery, when the initial response to 
feeding would occur and gluconeogenic recycling appears to be most vital. This would 
also indicate that PDK4 is not necessary for reducing PDHa activity following repletion 
of muscle glycogen, as PDHa activity had successfully decreased to resting levels in PF 
mice. 
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PDK4 may also play a role in regulating PDHa activity in the liver. Similar to 
results in skeletal muscle, hepatic PDHa activity increased similarily in WT and PDK4-
KO mice from exhaustion to recovery with greater PDHa activity in only PDK4-KO mice 
between these two time-points. Although PDK4 is believed to be the PDK isoform 
responsible for decreasing PDHa activity during nutritional perturbations in skeletal 
muscle, research has previously indicated that this role may fall more predominantly on 
PDK2 in the liver (102). Glycogen resynthesis in the liver, however, appears to indirectly 
rely on proper regulation of PDH in skeletal muscle to produce alanine and lactate for 
gluconeogenic recycling. In the PF group, WT-matched caloric intake and the absence of 
PDK4 led to decreased production of lactate and alanine in skeletal muscle as well as 
decreased lactate concentrations in the blood. Reduced availability of these precursors did 
not affect lactate and alanine concentrations in the liver, however hepatic glucose and 
glycogen concentrations were lower in the PF group. This suggests that the liver requires 
greater concentrations of lactate and alanine for sufficient gluconeogenic activity and that 
liver prioritizes the maintenance of blood glucose concentrations over maintaining 
hepatic glucose concentrations for glycogen resynthesis.  
In summary, this study examined the role of PDK4 in regulating the PDH 
complex during recovery from glycogen-depleting exercise and provides evidence that 
PDK4 may be important in fine-tuning the activation of PDH in skeletal muscle to allow 
for balance between carbohydrate oxidation and gluconeogenic precursor formation, 
promoting further glycogen resynthesis in both skeletal muscle and the liver.  
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 CHAPTER 5 - General Discussion 
 This study demonstrated that PDK4 plays a role in regulating carbohydrate 
metabolism post-exercise, as PDK4-KO mice must intake 2-fold more calories than WT 
control mice during a two-hour recovery period to adequately recover their glycogen 
stores. Furthermore, if PDK4-KO mice are pair-fed with WT mice, liver glycogen 
remains near depletion following the recovery period and both skeletal muscle and blood 
have lower concentrations of key gluconeogenic precursors. It should be noted that we 
had hypothesized to see larger differences in PDHa activity in skeletal muscle between 
genotypes, especially at two-hours of recovery, however the activation state of PDH may 
have been influenced by other factors, such as the concentration of insulin or the 
complete resynthesis of muscle glycogen observed in both genotypes. This would suggest 
that an earlier recovery time-point, perhaps at one-hour, may have provided a better 
sampling point for observing differences in PDHa activity between genotypes. Previous 
research has demonstrated sufficient recovery of glycogen in rat skeletal muscle after 
one-hour of recovery, with only small increases in resynthesis thereafter (11, 87). Pilot 
data for this study in WT and PDK4-KO mice, however, demonstrated different eating 
patterns between genotypes during one-hour of recovery (Table 5), and although not 
statistically different, the absence or presence of eating during recovery could 
significantly alter the degree of PDH activation by insulin (14, 57, 83) and therefore the 
rate of carbohydrate oxidation during that period. Furthermore, two-hours of recovery in 
this study was beneficial in measuring differences in feeding between WT and PDK4-KO 
mice, which provided evidence that larger caloric consumption following exercise was 
needed for the same degree of resynthesis in PDK4-KO mice. This observation led to the 
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inclusion of our PF group, which displayed impaired glycogen resynthesis in the liver, 
providing greater support on the important role PDK4 plays in skeletal muscle during 
recovery from glycogen-depleting exercise to favour glycogen resynthesis in both muscle 
and liver. It would be interesting to examine the same measurements in these mice after 
one-hour or less of recovery, however without the availability of food, to observe the role 
PDK4 plays in promoting gluconeogenic recycling of carbohydrates without insulin-
stimulation of the PDH complex. The absence of feeding might pose a problem, however, 
if prolonged, as PDK4 has been shown to be important during fasting (49, 113), which 
also produces decreased liver glycogen concentrations (43, 49), increased circulation of 
FFAs (53, 107), and a reliance on PDK4 to decrease PDHa activity (41, 42, 49, 113). 
 
Mouse WT Intake (g) KO Intake (g) 
1 0.3 0.12 
2 0 0 
3 0.04 0.02 
4 0 0.31 
5 0 0.71 
Mean ± SD 0.07 ± 0.13 0.23 ± 0.29 
 
Table 5 – Pilot post-exercise food consumption (grams) in wild-type 
(WT) and PDK4-KO (KO) mice during 1-hour of recovery after glycogen 
depleting exercise. 
 
In addition to PDHa activity, glycogen content, and metabolite concentrations, it 
may have also been beneficial to take blood samples for determination of glycerol and 
FFA concentrations. In addition to lactate and alanine, glycerol is also a prominent 
gluconeogenic precursor. Studies using DCA to increase the degree of PDHa activation 
during exercise recovery in rodents have noticed decreases in lactate, alanine, and 
glycerol (26), suggesting that this substrate may have been effected in PDK4-KO mice 
  
47 
during recovery. However, where fasting blood lactate and alanine concentrations have 
been shown to be impaired in PDK4-KO mice after an 18-week high-fat diet, glycerol 
concentrations contrarily remained consistent with controls (48). As PDK4 was also 
shown to be necessary in reducing PDHa activity with high-fat feeding, these results 
further suggest that no changes in glycerol would have been seen in the present study. 
Previous studies with these mice have demonstrated that PDK4-KO mice have higher 
circulating concentrations of FFA then WT controls during fasting and high-fat feeding 
(48, 49). Furthermore, PDK4-KO mice show no changes in the stimuli for FFA 
mobilization, however they display decreased FFA uptake and oxidation when compared 
to WT mice (48). As FFAs have been shown to be elevated following exercise (52, 70), it 
is possible that greater plasma concentrations would be observed in PDK4-KO mice than 
WT mice at exercise exhaustion and recovery.  
 In addition to skeletal muscle, the heart also expresses PDK4 in abundance (9) 
and glycogen concentrations in the heart have been shown to decrease as a result of 
exercise (19, 98, 99). Therefore the role of PDK4 in recovery of heart glycogen post-
exercise was also examined in this study as described for muscle and liver. Although 
glycogen concentrations did not significantly decrease in either genotype by exhaustion, 
all recovery groups experienced a ~3.8-fold supercompensation in glycogen 
concentrations by two-hours (Figure 11). From this it could be theorized that PDK4 does 
not play an essential role in the heart during exercise recovery, however the heart is one 
of few tissues to experience a compensatory upregulation from PDK2 in PDK4-KO mice 
(49) and therefore investigating the role of PDK4 in the hearts of PDK4-KO mice is 
somewhat problematic. Furthermore, glycogen in the heart is concentrated towards the 
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conduction system and the bundle of HIS (47), making it necessary to devote whole-heart 
tissue to the analysis of glycogen. This reduces the number of measurements that can be 
done on the heart without significantly increasing sample size, leaving the role of PDK4 
in the heart during exercise recovery unknown.  
 
 
 
Figure 11 – Glycogen concentrations in the heart at rest, exhaustion (Exh), and 
recovery (Rec) from exercise (n = 5-8). WT, wild-type; PDK4-KO, PDK4-knockout; 
PF, pair fed PDK4-KO.  Values are presented as mean ± S.E.  Different than rest 
within a genotype.  
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Future research should be directed at examining the balance between PDK4 and 
the PDPs during different exercise and dietary perturbations, focused on isolating the 
factors that would affect a reduced ability to activate the PDH complex. This effect 
appears be more prominent with chronic diabetes, as studies have demonstrated increased 
PDK4 expression (95, 113, 114) along with a decreased capacity to increase PDHa 
activity (35) in the diabetic state. Furthermore, as this is one of few studies to 
demonstrate a fine-tuning effect for PDK4 during exercise and recovery, this 
phenomenon should be further investigated through manipulating the expression of 
PDK4 and the PDP isoenzymes. 
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Appendices 
Appendix A – Mouse Chow Composition 
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Appendix B – Methods 
a. Metabolite Extraction 
I. Reagents 
 
0.5 M PCA  21.5 ml 70% PCA 
   Bring to 500 ml with distilled H20 
   Store 0-4ºC for 1 month 
 
2.3 M KHCO3    2.3 g KHCO3    
   Add 10.0 ml distilled H20 
   Fresh Daily 
 
II. Procedure 
 
1. Freeze dry tissue (overnight to ensure all water is removed) 
2. Store with dry rite in freezer until powdering 
3. Tease out connective tissue and powder 
4. Place in pre-weighed microcentrifuge tube and weigh (3-5mg) 
5. Place tubes in an ice bucket (make sure tubes remain cold) 
6. Add 600 μL of pre-cooled 0.5 M PCA 
7. Extract for 10 minutes, vortexing several times (ensure all tissue is in contact with 
PCA) 
8. Centrifuge for 10 minutes at 15 000 G (spinning helps remove some of the enzymes 
that can influence concentration) 
9. Remove 540 μL and place in freezer (-20ºC) for 10 min 
10.  To the frozen supernatant add 135 μL of 2.3 M KHCO3 and vortex until liquid 
(addition of KHCO3 to a frozen supernatant prevents foaming over) 
11. Centrifuge 10 min 0ºC at 15 000G. Remove supernate to assay metabolites. 
 
Dilution Factor = DFa x DFb 
DFa = V(PCA)/Muscle Mass (mg)      DFb=V(supernatant) + V(KHCO3)/V(supernatant) 
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b. Hydrolysis of Tissue for Glycogen Assay 
A. Reagents 
 
2.0 N HCl                                 To 83 ml water add 17 ml HCl (37% or 12 N) 
 
2.0N NaOH                              To 8 g NaOH add 100 ml water 
 
B. Procedure 
 
1. Use frozen tissue or tissue residue from perchloric acid extract or freeze dried 
powdered tissue.  
 
2. Add tissue to a microfuge tube (Not to exceed 5 mg dry weight).  
 
3. Add 500 μL 2 N HCl 
 
4. Record weight of each tube 
 
5.  Place at 100°C for 2 hours. Mix after the first hour. 
 
6.  Re-weigh each tube and add water to achieve initial weight 
 
7. Add 500 μL 2N NaOH, mix well.  
 
8. Store at -90°C until analysis. 
 
 
Dilution Factor = 1000/ muscle weight (mg) 
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c. Muscle Glucose & G-6-P/ Glycogen Assay for Plate Reader Fluorometer 
HEXOKINASE 
Glucose + ATP --------------------------------------- Glucose-6-P + ADP 
 
                                                                      G-6-P-DH   
Glucose-6-P + NADP  --------------------------------------- Glucanolactone + NADPH   
 
Reagent STOCK 
CONC 
FINAL  
CONC 
VOLUME 
25ml 
VOLUME 
50 ml 
VOLUME 
100ml 
 
1. Tris   
(on shelf) 
(pH 8.1) 
stored in fridge 
 
1.00 M 
 
50 mM 
 
1.25 ml 
 
2.5 ml 
 
5.00 ml 
 
2. MgCl2 (on shelf) 
make fresh (.2033g/ml) 
 
1.00 M 
 
1 mM 
 
25 μL 
 
50 μL 
 
100 μL 
 
3. DTT (found in -20) 
stored in aliquots (-80) 
 
0.5 M 
 
0.5 mM 
 
25 μL 
 
50 μL 
 
100 μL 
 
4. ATP (found in -20) 
stored in aliquots (-80) 
 
300 mM 
 
 
300 μM 
 
 
4.14 mg 
 
8.27 mg 
 
16.54 mg 
 
5. NADP (found in -20) 
stored in aliquots (-80) 
 
50 mM 
 
50 μM 
 
25 μL 
 
50 μL 
 
100 μL 
 
6. G-6-P-DH  
found in fridge 
(Sigma G-5760) 
 
 
2660 U/ml 
 
0.02 U/ml 
 
See  
 
Procedure 
 
Below 
 
7. Hexokinase  
found in fridge 
(Sigma L-5500) 
 
1338 U/ml 
 
0.14 U/ml 
 
See 
 
Procedure 
 
Below 
                  
Note: Mix reagents 1-5 together. Bring to volume with distilled water and adjust to pH 
8.1.  
 
Preparation of Dilute Enzyme 
 
1. Add 1.5 uL of G-6-P-DH to a test-tube containing 1.5 ml of Reagent. Mix by 
inversion.  
 
2. Add 5.2 uL of Hexokinase to a test tube containing 1 ml of reagent. Mix by inversion.  
 
  
62 
Procedure for Assay 
 
Part 1.  
 
1. Fill three wells with a blank (10.00 μL dH2O per well) 
2.   a. Vortex each concentration mixture before pipetting 
 b. Fill the next five wells with 10.00μL of varying concentrations of 5μM/ 2.5 
μM Glucose standard (0.1mM, 0.2 mM, 0.4 mM, 0.8 mM, 1.2 mM) 
3. a. Vortex each concentration mixture before pipetting 
          b. Fill the next five wells with 10.00μL of varying concentrations of 5uM   
          G6P standard (0.1mM, 0.2 mM, 0.4 mM, 0.8 mM, 1.2 mM) (only if determining 
G6P-DH) 
4.  a. Vortex each sample before pipetting 
b. Add 10.00 μL of sample to the appropriately wells 
5. Add 185 μL of buffer to each well 
6. Incubate for 15 minutes  
7. Read the plate at a sensitivity of 95 (excitation setting 340, emission setting 460) 
(base line reading) 
 
Part 2.  
 
1. Add 5 μL of dilute G-6-P-DH to all of the wells  
2. Place in the dark for 17 minutes 
3. Read the plate (excitation setting 340, emission setting 460) 
 
Part 3.  
 
1. Add 5 μL of dilute Hexokinase to all of the wells  
2. Place in the dark for 20 minutes 
3. Read the plate (excitation setting 340, emission setting 460) 
 
Note: Everything analyzed in triplicate 
 
Glucose Standard Curve (for glycogen) 
2.5 mM stock (25 mg of glucose (Sigma G 8270) to 55.2 ml of dH2O) 
 
Conc (mM) Stock (uL) dH2O (umol L
-1
) 
0.1 40 960 
0.2 80 920 
0.4 160 840 
0.8 320 680 
1.2 480 520 
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Glucose Standard Curve (for glucose) / G-6-P Standard Curve (for metabolite-extraction 
analysis only) 
2.5 mM glucose stock (25 mg of glucose (Sigma G 8270) to 55.2 ml of dH2O) 
2.5 mM G-6-P stock (42.04mg of G-6-P (Sigma G7375) into 50ml of dH2O) 
 
Conc (mM) Stock ( L) dH2O ( mol L
-1
) 
0.0125 5 995 
0.025 10 990 
0.05 20 980 
0.1 40 960 
0.2 80 920 
0.3 120 880 
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d. Muscle Lactate Assay for Plate Reader Fluorometer 
 LDH 
Lactate + NAD
+
 --------------------------------------- Pyruvate + NADH + H+ 
 
                                                       
PYRUVATE + Hydrazine --------------------------------------- Pyruvate Hydrazone   
 
Reagent STOCK 
CONC 
FINAL  
CONC 
VOLUME 
25ml 
VOLUME 
50 ml 
VOLUME 
100ml 
 
1. Hydrazine  
(on shelf) 
stored in fridge 
 
1.00M 
 
100.0 mM 
 
2.5 ml 
 
5.00 ml 
 
10.00 ml 
 
2. Glycine  
(on shelf) 
stored in fridge 
 
1.00 M 
 
100.0 mM 
 
2.5 ml 
 
5.00 ml 
 
10.00 μL 
 
3. NAD
+  
(found in -20) 
stored in aliquots ( -80) 
 
50.0 mM 
 
0.5 mM 
 
250 μL 
 
500 μL 
 
1000 μL 
 
4. LDH  
(found in fridge) 
Sigma L-2500 
 
13110 U/ml 
 
 
8 U/ml 
 
See 
 
Procedure 
 
 
 
Note: Mix reagents 1-3 together. Bring to volume with distilled water and adjust to pH 
10.  
 
Preparation of Dilute Enzyme 
 
Add 17.25 μL of LDH to 1.0 ml of reagent. Mix by inversion.  
(use 60 μL if using L-5132, LDH) 
 
Procedure for Assay 
 
Part 1.  
 
1. Fill three wells with a blank (10.00 μL dH2O per well) 
 
2.   a. Vortex each concentration mixture before pipetting 
b. Fill the next five wells with 10.00μL of varying concentrations of lactate 
standard (see below) 
 
3.  a. Vortex each sample before pipetting 
b. Add 10.00 μL of sample to the appropriately wells 
 
4. Add 185 μL of buffer to each well 
5. Incubate for 15 minutes  
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6. Read the plate at a sensitivity of 100 (excitation setting 340, emission setting 460) 
(base line reading) 
 
Part 2.  
 
1. Add 10 μL of dilute LDH to all of the wells  
 
2. Place in the dark for 120 minutes 
 
3. Read the plate (excitation setting 340, emission setting 460, sensitivity 100) 
 
 
Note: Run everything in triplicate 
 
Lactate Standard Curve 
Pre-made lactate standard (4.44 mM) 
 
Conc (mM) Stock (uL) dH2O (umol L
-1
) 
0.1 23 977 
0.2 45 955 
0.4 90 910 
0.8 180 820 
1.2 270 730 
 
 
Conc (mM) Stock (uL) dH2O (umol L
-1
) 
0.025 5.6 994 
0.05 11.25 988 
0.1 22.5 978 
0.2 45 955 
0.4 90 910 
0.8 180 820 
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e. Muscle Alanine Assay for Plate Reader Fluorometer 
Alanine Aminotransferase 
Alanine + 2-Oxogluterate --------------------------------------- Pyruvate + Glutamate 
 
LDH 
Pyruvate + NADH + H
+
 --------------------------------------- Lactate + NAD+  
 
Reagent STOCK 
CONC 
FINAL  
CONC 
VOLUME 
25ml 
VOLUME 
50 ml 
VOLUME 
100ml 
 
1. Tris HCl  
 
 
1.00 M 
 
25 mM 
 
0.625 mL 
 
1.25 mL 
 
2.5 mL 
 
2. Tris Base 
 
 
1.00 M 
 
25 mM 
 
0.625 mL 
 
 1.25 mL 
 
2.5 μL 
 
3. 2-Oxogluterate 
Sigma K3752 
Make fresh 190mg/ml 
 
 
10.0 mM 
 
50 μM 
 
125 μL 
 
250 μL 
 
500 μL 
 
4. NADH 
Sigma N-8129 
make fresh 3.6 mg/ml 
 
 
5.0 mM 
 
15 μM  
 
75 μL 
 
150 μL 
 
300 μL 
 
5. LDH 
Sigma L2500 
 
 
13110 U/ml 
 
0.25 U/ml 
 
0.5 μL 
 
1 μL 
 
2 μL 
 
6. Alanine 
Sigma G9880 
 
 
 
    
 
7. Glutamic-Pyruvic 
Transaminase 
(GPT) 
Sigma 9880 
 
 
15.1mg 
protein/ml; 
88units/mg 
protein 
 
5 U/ well 
   
 
Note: Mix reagents 1-2 together, bring to volume with distilled water, adjust pH to 8.1, 
and add reagents 3-5. 
 
Preparation of Dilute Enzyme 
 Add 188.14 μL of GPT (Sigma G9880) to 1mL of reagent. Mix by inversion. 
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Procedure for Assay 
 
Part 1.  
 
1. Fill three wells with a blank (10.00 μL dH2O per well) 
 
2.   a. Vortex each concentration mixture before pipetting 
b. Fill the next five wells with 10.00μL of varying concentrations of the alanine 
standard (see below) 
 
3.  a. Vortex each sample before pipetting 
b. Add 10.00 μL of sample to the appropriate wells 
 
4. Add 185 μL of buffer to each well 
5. Incubate for 30 minutes  
6. Read the plate at a sensitivity of 100 (excitation setting 340, emission setting 460) 
(base line reading) 
 
Part 2.  
 
1. Add 10 μL of dilute GPT to all of the wells  
 
2. Place in the dark for 2 hours 
 
3. Read the plate (excitation setting 340, emission setting 460, sensitivity 100) 
 
 
Note: Run everything in triplicate 
 
Alanine Standard Curve 
2.5 mM alanine standard: dissolve 44.55mg of alanine into 200ml dH2O. 
 
Conc (mM) Stock ( L) dH2O ( mol L
-1
) 
0.0125 5 995 
0.025 10 990 
0.05 20 980 
0.1 40 960 
0.2 80 920 
0.3 120 880 
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f. Determination of PDH Activity 
(1) PDH Assay Buffer (for both active and total determinations) 
 
Reagent M.W. [final], mM Amt/200 mL
Tris 121.1 144.4 3.4974 g
EDTA 372.24 0.72 0.0536 g
MgCl2 203.3 1.44 0.0586 g
 pH to 7.8 with HCl, and freeze in 4 ml aliquots at -20 C. 
 
(2) PDHa Homogenizing Buffer 
 
Reagent M.W. [final], mM Amt/100 mL
Sucrose 342.3 200 6.8460 g
KCl 74.55 50 0.3728 g
MgCl2 203.3 5 0.5083 g
EGTA 380.4 5 0.1902 g
Tris HCl 121.1 50 0.6055 g
NaF 41.99 50 0.2100 g
DCA 12.1 M stock 5 41.3 ul
Triton X-100 0.10 ml 0.1% (v:v) 0.10 ml
 pH to 7.8 with NaOH and freeze in aliquots at -20 C 
 
3) PDHt Homogenizing Buffer (**cannot be used with resting samples) 
 
Reagent M.W. [final], mM Amt/100 mL
Sucrose 342.3 200 6.8460 g
KCl 74.55 50 0.3728 g
MgCl2 203.3 25 0.5083 g
EGTA 380.4 5 0.1902 g
Tris HCl 121.1 50 0.6055 g
Glucose 180.16 10 0.1802 g
DCA 12.1 M stock 5 41.3 ul
CaCl2 147.02 10 0.1470 g
Triton X-100 0.10 ml 0.1% (v:v) 0.10 ml
 pH to 7.8, and freeze in aliquots at -20 C. 
Add hexokinase daily (sulphate free);  prepare 820 U/ml stock and store at -20 C. 
Stable for 30 d of repeated freezing and thawing. 
 
 
 
*Note:  1) NaF, phosphatase inhibitor; 2) DCA, kinase inhibitor;  3) Triton, digest 
membrane phospholipids to facilitate release of membrane-bound PDH; 4) CaCl2 and 
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MgCl2, provide divalent ions for phosphatase activation; 5) glucose and hexokinase, 
elimination of endogenous ATP. 
Homogenization Procedure (active and total): 
 
N.B.  Prior to homogenization, try to dissect each sample free of all connective tissue and 
dried blood, etc.  Total Cr content should be measured from each homogenate, and all 
values for a subject corrected to the highest Cr value.  Note that the picric acid method of 
determining total Cr is not suitable for these homogenates.  See below for total Cr 
determination. 
 
1. Place 100 l of homogenizing buffer (use the appropriate buffer, for either the 
transformed (active) or total activity) into a homogenizing mortar, depending on 
sample size.  NOTE: total PDH activity is not measurable on resting samples. 
 
2. Place the tube in small Styrofoam block, place all on a weighing balance and tare it. 
 
3. Add 5-10 mg of wet, frozen muscle to the tube, and record its weight (mg). 
 
4. Multiply weight of muscle by 30, then subtract 100 from this total (for the 100 l of 
buffer that has already been added) and add the remaining amount of cold 
homogenizing buffer (kept on ice) to the sample in the mortar. 
 (eg. 10 mg muscle sample – 30X10 mg = 300 l to be added – 100 l already added = 
200 l more to be added)  
 
5. Begin homogenization of the sample with gentle twisting hand movements (on ice).  
NOTE: the time between weighing and homogenizing should be kept to a minimum. 
 
6. Thereafter, homogenize for 50s with a motor-driven glass pestle at ~20-30 rpm (on 
ice). 
 
7. Store the homogenate in an eppendorf tube (with small hole in top) in liquid N2 and 
analyze for PDH activity (within 1-2 d).  It is very important to immediately "snap-
freeze" the homogenates in liquid N2 to prevent reformation of vesicles.  
Approximately 50% of these reformed vesicles will be "inside-out", masking the PDH 
complex within the vesicle and resulting in PDH activities of ~50% of that expected.  
Similarly thaw samples one at a time, just prior to analysis to prevent vesicle 
formation at room temperature. 
 
8. After completion of PDH measurements, the remaining homogenate should be kept at 
-80 C for total Cr determination. 
 
Determination of total Cr. 
 
1. Thaw homogenates at room temperature; vortex. 
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2. Add 30 l of homogenate to 30 l of 0.5 N PCA with (with EDTA). 
 
3. Vortex well, and let sit at room temperature for 60 min (PCr is hydrolyzed to Cr at 
this stage). 
 
4. Neutralize with 7.5 l of 2.2 M KHCO3, vortex, and centrifuge to separate salt from 
the supernatant. 
 
5. Measure Cr photometrically with enzymatic method.  If desired, PCr can be measured 
on a few randomly chosen samples to insure that its hydrolysis was complete. 
 
 
Determination of PDH Activity (active and total) 
 
1) Preparation of PDH Reagent (choose (A) or (B) below): 
(A) For PDHa activity in frozen muscle samples, for a given sample (homogenate), 
there are duplicate (2) incubations for the determination of PDH activity, plus 1 blank 
(total of 3 incubations).  Assume a requirement of 0.72-1.0 ml of reagent* mixture per 
incubation when preparing solutions. 
Reagent 
Mixture*
M.W. 
(g/mol)
Stock, mM
Stock, 
mg/mL
Vol. for 12 
incubations
Vol. for 18 
incubations 
Vol. for 24 
incubations
Vol. for 30 
incubations
PDH Assay 
Buffer
9 mL 13.5 mL 18 mL 22.5 mL
NAD 717.4 39 28 1 mL 1.5 mL 2 mL 2.5 mL
CoASH 767.6 13 10 1 mL 1.5 mL 2 mL 2.5 mL
TPP 460.8 13 6 1 mL 1.5 mL 2 mL 2.5 mL
TOTAL 12  mL 18 mL 24 mL 30 mL
Pyruvate** 110 26 3.1 0.5 ml 0.75 ml 1.0 ml 1.25 ml
*  Reagent mixture is comprised of PDH assay buffer, NAD, CoASH and TPP. 
**Pyruvate is added to initiate the reaction through PDH. 
 
(B) For PDHa determination as part of a PDK Assay: 
 - PDH measurements as part of the PDK assay need one to be done in duplicate 
(blank is always zero).  For these assays, afford at least 0.26 ml of reagent per 
incubation. 
  
71 
Reagent 
Mixture*
M.W. 
(g/mol)
Stock, mM
Stock, 
mg/mL
Vol. for 16 
Samples***
Vol. for 24 
Samples***
Vol. for 32 
Samples***
PDH Assay 
Buffer
8 mL 12 mL 16 mL
NAD 717.4 39 28 0.9 mL 1.35 mL 1.8 mL
CoASH 767.6 13 10 0.9 mL 1.35 mL 1.8 mL
TPP 460.8 13 6 0.9 mL 1.35 mL 1.8 mL
TOTAL 10.7  mL 16.05 mL 21.4 mL
Pyruvate** 110 26 3.1 0.5 ml 0.75 ml 1.0 ml
*  Reagent mixture is comprised of PDH assay buffer, NAD, CoASH and TPP. 
**  Pyruvate is added to initiate the reaction through PDH. 
***16 samples (for example) indicates 2 biopsies x 8 PDHa’s/biopsy x duplicate = 32 
incubations 
 
2) Incubation of Samples: 
 
1. Pre-heat block heater to 37 C.  Monitoring of the temperature may be facilitated by 
the placement of a thermometer sealed by parafilm in a tube of water, which is then 
left in one of the holders of the block heater for the duration of the incubations. 
 
2. For each sample (homogenate), the reaction will be run in duplicate (initiated with 
pyruvate) and with one blank (initiated with water).  To determine the reaction rate, 
acetyl-CoA production will be determined at the precise intervals of 1, 2 and 3 min 
after the initiation of the reaction.  Therefore, use coloured eppendorf tubes (1 
(white), 2 (green), and 3 (blue) min) for each of the duplicates (A, B) and blank (C), 
if necessary.  e.g. the 3 min determination of duplicate B would be a blue tube 
labeled, "B" along with the sample information.  **note: there are no blanks run 
with PDK assays** 
 
3. Pipette 40 l of 0.5 N PCA into each of the labeled tubes and place in a separate 
rack. 
 
4. Pipette correct amount of reagent into 12x75 culture tubes in block heater and allow 
it to warm for sufficient time (at least 3 incubations).   Be sure to warm more as you 
proceed with the PDHa’s!  The pyruvate (~150 l) should also be warmed in the 
block heater for at least a period of 3 incubations, but in a separate and distinct tube. 
 
5. A) For a PDHa Assay, add 30 l of the homogenate (using a positive displacement 
pipetter) into 720 l of pre-warmed reagent mixture.  Mix well by drawing up and 
ejecting from the pipetter several times, or by vortexing (very gently (foaming 
indicates denaturing of the protein.). 
  
72 
B) For a PDK Assay, add 15 l of the homogenate with a positive displacement 
pipetter into 260 l of pre-warmed reagent mixture.  Mix well by drawing up and 
ejecting from the pipetter several times. 
 
6. A) For a PDHa Assay, initiate the reaction by adding 30 l of pyruvate.  Vortex 
very gently and start the timer.  It is not crucial that the timer is started immediately 
upon the addition of pyruvate (i.e. within a few seconds). It is extremely important, 
however, than once the timer has begun, samples of the incubating solution are 
obtained at precisely timed 1 min intervals, for determination of the slope (reaction 
rate).  Variability in the exact starting time of the reaction will merely cause slight 
deviations in the y-intercept from 0. 
 B) For a PDK Assay, follow the same procedure, but start with only 15 l of 
pyruvate. 
 
7. A) For a PDHa Assay, after precisely 1 min, draw 200 l of the incubation mixture 
and pipette into the appropriately labeled eppendorf tube containing PCA.  Vortex, 
and let sit at room temperature until the entire incubation trial is complete. 
 B) For a PDK Assay, after precisely 1 min, draw 70 l of the incubation mixture 
and pipette into the appropriately labeled eppendorf tube containing PCA.  Vortex, 
and let sit at room temperature until the entire incubation trial is complete. 
 
8. Repeat step #7 at precisely 2 and 3 min into the incubation. 
 
9. Repeat steps #5 to #8 so that the entire procedure is run in duplicate. 
 
10. Run a blank when necessary for each homogenate by repeating steps #5 to #8, 
substituting 30 l of water for pyruvate. 
 
11. Neutralize samples with 10 l of 1 M K2CO3 to each of the tubes and vortex.  
Allow the acidified homogenates to sit for 5 min before neutralization to fully stop 
the reaction. 
 
12. Store neutralized extracts at -80 C until analyzed for acetyl-CoA content.  Acetyl-
CoA is viable for ~1 wk at this temperature.  Prior to analysis, thaw samples and 
vortex. 
 
13. NOTE:  Incubation of duplicates and blank can be run simultaneously, if the 
initiation of the reactions are staggered such that the sampling times of each (@ 1, 2, 
and 3 min) are separated by ~15 - 20 s. 
 
14. Use the following dilutions for acetyl-CoA determinations:     
 
 a) human PDHtot and PDHa (exercise):  10 l extract + 190 l water 
 b) human PDHa (rest):  20 l extract + 200 l water 
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f. Herbst's Guide to Western Blotting 
 
Sample Preparation: 
Homogenization 
1. Make up homogenization buffer: 
 250mM sucrose = 21.4g 
 100mM KCl = 1.865g 
 5mM EDTA = 0.4695 
 add 225mL dH2O, fix pH 6.8, top up to 250mL dH2O and mix well, store 
in fridge 
2. Remove wanted buffer and add protease inhibitor tablet (from antibody drawer) 
(Roche, 1 tablet /10mL) and add phosphatase inhibitor (Roche, 1 tablet /10mL) 
3. Prepare glass homogenizers with ~ 200 L of buffer, tear in scale, remove ~ 10mg 
chunk of muscle from sample for analysis, add muscle and weigh 
 keep on ice when possible 
4. Correct buffer volume in homogenizer so that 10 L of buffer is present for every 
1mg of sample 
5. Homogenize well on ice 
 
Protein Determination: 
1. Make up or remove BSA standard (1mg/ml) from -20 
2. Make up standard: 
Final Protein 
Concentration (mM) 
Volume of BSA ( L) Volume of dH2O ( L) 
1 leave as is 0 
0.5 500 from '1' 500 
0.25 500 from '0.5' 500 
0.125 500 from '0.25' 500 
0.05 100 from '0.5' 900 
0 0 Leave as is 
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3. Pipette everything in triplicate in a clear microtitre plate. Pipette the samples as 
9 L of dH2O and 1 L of sample for whole homogenate (10x dilution), 9.5 L of 
dH2O and 0.5 L of sample for mitochondrial suspension (20x dilution). 
4. Add 200 L of diluted buffer (1:4 with Bio-Rad Protein Assay Dye Reagent : 
dH2O) 
5. Let incubate for 5min and read absorbance as wavelength 595nm 
6. In excel run polynomial curve with blanks subtracted, multiply determined y-
intercept by 10 to determine protein concentration for whole homogenates, by 20 
for mitochondrial isolations. 
7. To prep samples for blotting1 (best done on same day as SDS PAGE): 
Total Volume (TV) Optional 25 - 100 L 
Sample Volume (SV) SV = TV
[Desired Final Protein]
[Protein]
 
Sample (Laemelli) Buffer (SB) SBf
TV
[SBi]
 (i.e. 
TV
5
 for 5x SBi) 
Water (dH20) dH2O TV SV SB 
1M DTT
 2**
 = 10% of total volume 
 
SDS PAGE Procedure: 
Electrophoresis Preparation 
1. Before using glass plates, wipe with methanol and a kimwipe 
2. Assemble the glass-holding apparatus with the short plate facing front. Ensure 
plates are flush and level before locking and inserting onto the gel casting stand 
3. Prepare gels (makes 2): 
Percent Gel dH2O (ml) Protogel (ml) 
(30% acrylamide) 
Gel Buffer (ml) 
 
  4 (Stacking) 6.1 1.3 2.5 Stacking 
  6 5.3 2.0 2.5 Resolving 
  8 4.62 2.67 2.5 Resolving 
  10 (Running) 3.96 3.33 2.5 Resolving 
                                                 
1
 If [protein] is <1, cannot reliably perform blotting 
2
 DTT is optional. Effects redundant with -mercaptoethanol (in Laemelli buffer) 
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  12 3.29 4.0 2.5 Resolving 
  15 2.29 5.0 2.5 Resolving 
 
4. Before pouring the running gel, add 100 L APS (60mg/600 L) and 10 L of 
TEMED. Swirl and pour until reaching the depth of the comb. Use methanol to 
remove any bubbles and dump once hardened 
5. Before pouring the stacking gel, add 100 L APS and 20 L TEMED. Swirl and 
pour until the top of the short plate is reached. Insert combs of desired size. Once 
hardened, remove combs and rinse with dH2O 
6. Place gel cassettes into electrode assembly with the short plates facing inwards, 
clamp down firmly and place into mini-tank 
7. Boil samples for 5-minutes and place subsequently on ice for 5-minutes while 
preparing running buffer (50mL 10x running buffer + 450mL dH2O) 
8. Fill the inner chamber of the apparatus with diluted running buffer add ~200mL 
to the outside chamber 
9. Load the standard3 and the appropriate amount of sample into each well. (Note: to 
determine the appropriate amount of sample to load, perform a separate 
optimization with varying amounts of protein. 5-10 L may be used successfully if 
just practicing). 
10. Run electrophoresis at 120-volts for 90-minutes or until the blue dye travels to the 
bottom edge of the plate. If tiny bubbles rise then electrophoresis is working
4
. 
Prepare transfer buffer. 
 
Transfer 
1. Remove gels carefully, discard the stacking gel, and transfer to a plastic try to 
equilibrate in transfer buffer 
                                                 
3
 Lui says: "5 L works nicely" 
4
 Thing's aren't going well if: 
- the amount of buffer inside the tank is going down (you have a leak!) 
- the bands form a "sad face" (you may be running the gel at too high a voltage or 
have a leak) 
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2. Create the "transfer sandwich": 
 white/clear side of the holder 
 sponge/ fibre pad (presoaked in transfer buffer) 
 filter paper (presoaked in transfer buffer) 
 membrane (PVDF presoaked in methanol) 
 Gel 
 filter paper (presoaked in transfer buffer) 
 sponge/ fibre pad (presoaked in transfer buffer) 
 black side of the holder 
*Be sure to roll out any air bubbles, close firmly, and place the black side of the 
holder to the black (/back) side of the electrophoresis apparatus. 
3. Fill the tank with transfer buffer and the surrounding environment with plenty of 
ice to prevent from cooking the gel and add a stir-bar to help with heat loss. 
4. Run the transfer at 100-volts for 60-minutes 
 
Antibodies 
1. Discard the gel and filter papers and transfer the membranes to small dishes 
2. Block with 20mL TBST-5% skim milk5 or TBST-3% BSA solution (4.5g skim 
milk powder in 90mL) for 1-hour 
3. Discard blocking solution and add 1o AB in TBST-5% skim milk, incubating for 
1-hour or overnight
6
 with the appropriate dilution 
Antibody Size (kDa) Dilution Amount ( L in 10mL) 
PDK 1-4 46-48 1:200 50
7
 
PDP1c 53 1:3000 3.3 
PDP2 60 1:3000 3.3 
PDH E1  41 1:5000 2 
PDH E2 52 1:5000 2 
PDH E2/E3bp 50 1:1000 10 
                                                 
5
 Can substitute with a TBST-3% BSA solution (3.0g BSA in 100mL TBST) 
6
 McMeekin says: "overnight works better" 
7
 Dunford used 5 L in 10mL successfully 
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CS 50 1:500 20 
COX (subunits 2-4) 20-26 1:000 10 
ANT 30 1:200 50
8
 
 
4. Wash 3-5x 5-minutes with TBST (10mL) 
5. Add 2o Ab (dependent on 1o Ab) in TBST-5% skim milk solution for 1-hour with 
the appropriate dilution 
Secondary Dilution Amount ( L in 10 mL) 
Anti-mouse 1:5000 2 
Anti-goat 1:20000 0.5 
Anti-rabbit 1:10000 1 
 
 
Enhanced Chemiluminesence 
1. Wash 3x 5-minutes with TBST 9 
2. Combine 1mL of each chemiluminescent HPR substrate (peroxide solution + 
luminal reagent) over membrane and continue to pipette over membrane or let 
rock for 5-minutes 
3. Place membrane protein-side down on glass and cover back with parafilm 
4. Take an initial photo with a pin beside the standard that represents the weight of 
your protein for overlapping later if need be. Take a subsequent photo with the 
appropriate exposure time and analyze later with "Imagej". 
                                                 
8
 Herbst used 10 L in 10mL successfully 
9
 Herbst says: In some instances, longer incubations in TBST produce cleaner blots 
(PDKs especially) 
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Reagents: 
 
Homogenizing Buffer 
- 250mM sucrose (21.4g) 
- 100mM KCL (1.865g) 
- 5mM EDTA (0.4695g) 
- add 225mL dH2O, fix pH 6.8, top up to 250mL dH2O 
- mix and store in fridge 
 
Laemelli Buffer (2x Sample Buffer) 
- 2.5ml 0.5M Tris-HCl pH 6.8 
- 2ml glycerol 
- 2ml 10% SDS 
- 0.2mL 1% bromophenol blue 
- 1ml -mercaptoethanol 
- 0.3mL dH2O 
 
Running Gel Buffer 
- 1.5M Tris-HCl, pH 8.8 
 
Stacking Gel Buffer 
- 0.5M Tris-HCl, pH 6.8 
 
10x Running Buffer, pH 8.3 
- 250mM Tris base 
- 1.92M glycine 
- 1% SDS 
- Store at 4oC. If precipitation occurs, warm to room temp before use. 
 
10x Transfer Buffer (semi-dry) 
- 312.5mM Tris base (3.786g) 
- 2.4M glycine (18g) 
- fill to 100mL with dH2O 
- *before use, dilute 80mL in 720 mL dH2O and add 200mL of methanol 
 
10x TBS 
- 200mM Tris base 
- 1.37M NaCl 
- 38mL of 1M HCl/L of TBS made 
- adjust to pH 7.5 
 
TBST 
- dilute 100mL of 10x TBS in 900mL dH2O 
- add 4mL of 25% Tween 20 while stirring (polyoxyethylenesorbitan monolaurate) 
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Appendix C – Western Blot Results 
 
 
Figure C.1 - Representative Western blots of PDK2 (top) and actin (bottom). Blots 
are plotted as WT, KO, WT, KO 
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Figure C.2 – Representative Western blots of PDP1 (top) and actin (bottom). Blots 
are plotted as WT, KO, WT, KO 
 
